DK1648507T3 - Fremgangsmåder og sammensætninger til øgning af effektiviteten af terapeutiske antistoffer ved anvendelse af forbindelser, der potenserer nk-celler - Google Patents

Fremgangsmåder og sammensætninger til øgning af effektiviteten af terapeutiske antistoffer ved anvendelse af forbindelser, der potenserer nk-celler Download PDF

Info

Publication number
DK1648507T3
DK1648507T3 DK04744267.8T DK04744267T DK1648507T3 DK 1648507 T3 DK1648507 T3 DK 1648507T3 DK 04744267 T DK04744267 T DK 04744267T DK 1648507 T3 DK1648507 T3 DK 1648507T3
Authority
DK
Denmark
Prior art keywords
antibody
cells
nkr
therapeutic
antibodies
Prior art date
Application number
DK04744267.8T
Other languages
English (en)
Inventor
Andrea Velardi
François Romagne
Original Assignee
Innate Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma Sa filed Critical Innate Pharma Sa
Application granted granted Critical
Publication of DK1648507T3 publication Critical patent/DK1648507T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Claims (31)

  1. FREMGANGSMÅDER OG SAMMENSÆTNINGER TIL ØGNING AF EFFEKTIVITETEN AF TERAPEUTISKE ANTISTOFFER VED ANVENDELSE AF FORBINDELSER, DER POTENSERER NK-CELLER
    1. Anvendelse af (a) et anti-NK-cellereceptor (NKR)-antistof, der bindes til og hæmmer aktiviteten af en hæmmende KIR2DL-receptor af en NK-celle, og (b) et terapeutisk antistof, der kan bindes ved hjælp af CD16 gennem dets Fc-region, og som depleterer målceller ved hjælp af ADCC, til fremstilling af et lægemiddel til behandling af en sygdom, hvor anti-NKR-antistoffet øger effektiviteten af det terapeutiske antistof ved forstærkning af ADCC, hvor anti-NKR-antistoffet bindes til en almindelig determinant af humane KIR2DL1-, KIR2DL2- og KIR2DL3-receptorer og hæmmer KIR2DL1-, KIR2DL2- og KIR2DL3-medieret inhibition af NK-celle-cytotoksicitet.
  2. 2. Anvendelse ifølge krav 1, hvor det terapeutiske antistof har en human IgGl eller en IgG3 Fc-del.
  3. 3. Anvendelse ifølge kravene 1 eller 2, hvor anti-NKR-antistoffet omfatter et antigenbindingsfragment deraf.
  4. 4. Anvendelse ifølge kravene 1 til 3, hvor det terapeutiske antistof er et monoklonalt antistof eller omfatter et antigenbindingsfragment deraf.
  5. 5. Anvendelse ifølge et hvilket som helst af de ovenstående krav, hvor det terapeutiske antistof ikke er konjugeret med en radioaktiv eller toksisk del.
  6. 6. Anvendelse ifølge et hvilket som helst af de ovenstående krav, hvor anti-NKR-antistoffet er et humant, humaniseret eller kimærisk antistof eller omfatter et antigenbindings fragment deraf.
  7. 7. Anvendelse ifølge et hvilket som helst af de ovenstående krav, hvor det terapeutiske antistof er et humant, humaniseret eller kimærisk antistof eller omfatter et antigenbindings fragment deraf.
  8. 8. Anvendelse ifølge et hvilket som helst af de ovenstående krav, hvor det terapeutiske antistof er rituximab eller alemtuzumab.
  9. 9. Anvendelse ifølge krav 8, hvor det terapeutiske antistof er rituximab og administreres i en dosis på mindre end 375 mg/m2 pr. uge.
  10. 10. Anvendelse ifølge krav 8, hvor det terapeutiske antistof er alemtuzumab og administreres i en dosis på mindre end 90 mg pr. uge.
  11. 11. Anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor anti-NKR-antistoffet bindes til det samme epitop som det monoklonale antistof DF200 fremstillet ved hybridom DF200, der er deponeret under registreringsnummer CNCM 1-3224.
  12. 12. Anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor anti-NKR-antistoffet konkurrerer med det monoklonale antistof DF200 fremstillet ved hybridom DF200, der er deponeret under registreringsnummer CNCM 1-3224, til binding til en KIR-receptor på overfladen af en human NK-celle.
  13. 13. Anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor anti-NKR-antistoffet er det monoklonale antistof DF200 fremstillet ved hybridom DF200, der er deponeret under registreringsnummer CNCM 1-3224, eller et fragment eller derivat deraf.
  14. 14. Anvendelse ifølge et hvilket som helst af de ovenstående krav, hvor det terapeutiske antistof og anti-NKR-antistoffet administreres samtidigt til individet.
  15. 15. Anvendelse ifølge et hvilket som helst af de ovenstående krav, hvor anti-NKR-antistoffet administreres til individet inden for én uge efter administration af det terapeutiske antistof.
  16. 16. Anvendelse ifølge et hvilket som helst af de ovenstående krav, hvor sygdommen er en cancer, eller en infektions- eller immunsygdom.
  17. 17. Anvendelse ifølge et hvilket som helst af de ovenstående krav, hvilken anvendelse endvidere omfatter vurdering af aktiviteten eller antallet af NK-celler i individet forud for eller efter administration af anti-NKR-antistoffet.
  18. 18. Anvendelse ifølge krav 17, hvor vurderingen af aktiviteten eller antallet af NK-celler involverer i) inkubation af NK-celler, der er opnået fra individet forud for administration i nærvær af den ene eller flere målceller, der er genkendt af det terapeutiske antistof, i nærvær eller fravær af anti-NKR-antistoffet; og ii) vurdering af effekten af anti-NKR-antistoffet på evnen for NK-cellerne til at depletere målcellerne; hvor en påvisning af, at anti-NKR-antistoffet øger evnen for NK-celleme til at depletere målcellerne indikerer, at anti-NKR-antistoffet er egnet til anvendelse i fremgangsmåden og fremgangsmåden er egnet til anvendelse til individet.
  19. 19. F armaceutisk s ammens ætning, der omfatter: (a) et terapeutisk antistof, der kan bindes ved hjælp af CD 16 gennem dets Fe-region, og som depleterer målceller ved hjælp af ADCC, (b) et anti-NK-cellereceptor (NKR)-anlistof, der bindes til og hæmmer aktiviteten af en hæmmende KIR2DL-receptor af en NK-celle, og (c) en farmaceutisk acceptabel bærer, hvor anti-NKR-antistoffet bindes til en almindelig determinant af humane KIR2DL1-, KIR2DL2- og KIR2DL3-receptorer og hæmmer KIR2DL1-, KIR2DL2-, og KIR2DL3-medieret inhibition af NK-celle-cytotoksicitet.
  20. 20. Sammensætning ifølge krav 19, hvor det terapeutiske antistof har en human eller ikke-human primat IgGl eller IgG3 Fc-del.
  21. 21. Sammensætning ifølge kravene 19 eller 20, hvor anti-NKR-antistoffet omfatter et antigenbindingsfragment deraf.
  22. 22. Sammensætning ifølge kravene 19 eller 20, hvor anti-NKR-antistoffet er et monoklonalt antistof eller omfatter et antigenbindingsfragment deraf.
  23. 23. Sammensætning ifølge kravene 19 til 22, hvor anti-NKR-antistoffet er et humant, humaniseret eller kimærisk antistof eller omfatter et antigenbindingsfragment deraf.
  24. 24. Sammensætning ifølge kravene 19 til 23, hvor det terapeutiske antistof er et monoklonalt antistof eller omfatter et antigenbindingsfragment deraf.
  25. 25. Sammensætning ifølge krav 24, hvor det terapeutiske antistof er et humant, humaniseret eller kimærisk antistof eller omfatter et antigenbindings fragment deraf.
  26. 26. Sammensætning ifølge kravene 24 eller 25, hvor antistoffet ikke er konjugeret med en radioaktiv eller toksisk del.
  27. 27. Sammensætning ifølge kravene 19 til 26, hvor det terapeutiske antistof er rituximab eller alemtuzumab.
  28. 28. Sammensætning ifølge krav 19, hvor anti-NKR-antistoffet bindes til det samme epitop som det monoklonale antistof DF200 fremstillet ved hybridom DF200, der er deponeret under registreringsnummer CNCM1-3224.
  29. 29. Sammensætning ifølge krav 19, hvor anti-NKR-antistoffet konkurrerer med det monoklonale antistof DF200 fremstillet ved hybridom DF200, der er deponeret under registreringsnummer CNCM I-3224, til binding til en KIR-receptor på overfladen af en human NK-celle.
  30. 30. Sammensætning ifølge krav 19, hvor anti-NKR-antistoffet er det monoklonale antistof DF200 fremstillet ved hybridom DF200, deponeret under registreringsnummer CNCM 1-3224, eller et fragment eller derivat deraf.
  31. 31. Anvendelse af et anti-NK-cellereceptor (NKR)-antistof, der blokerer for en hæmmende KIR2DL-receptor af en NK-celle, hvor anti-NKR-antistoffet bindes til en almindelig determinant af humane KIR2DL1-, KIR2DL2- og KIR2DL3-receptorer og hæmmer KIR2DL1-, KIR2DL2- og KIR2DL3-medieret inhibition af NK-cellc-cytotoksicitet til fremstilling af et lægemiddel til øgning af effektiviteten af en behandling, der involverer administration til et individ af et terapeutisk antistof, der kan bindes ved hjælp af CD16 gennem dets Fc-region, og som depleterer målceller hos individet ved hjælp af ADCC, hvor det terapeutiske antistof administreres til individet forud for, samtidigt med, eller efter en terapeutisk effektiv mængde af anti-NKR-antistoffet, og hvor anti-NKR-antistoffet øger effektiviteten af behandlingen ved forstærkning af ADCC hos individet.
DK04744267.8T 2003-07-24 2004-07-23 Fremgangsmåder og sammensætninger til øgning af effektiviteten af terapeutiske antistoffer ved anvendelse af forbindelser, der potenserer nk-celler DK1648507T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48948903P 2003-07-24 2003-07-24
PCT/IB2004/002636 WO2005009465A1 (en) 2003-07-24 2004-07-23 Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds

Publications (1)

Publication Number Publication Date
DK1648507T3 true DK1648507T3 (da) 2017-05-01

Family

ID=34102889

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04744267.8T DK1648507T3 (da) 2003-07-24 2004-07-23 Fremgangsmåder og sammensætninger til øgning af effektiviteten af terapeutiske antistoffer ved anvendelse af forbindelser, der potenserer nk-celler

Country Status (22)

Country Link
US (3) US7803376B2 (da)
EP (2) EP1648507B1 (da)
JP (3) JP5642328B2 (da)
KR (2) KR101299599B1 (da)
CN (3) CN102772798B (da)
AU (1) AU2004258747B2 (da)
BR (1) BRPI0412890B8 (da)
CA (1) CA2532547C (da)
CY (1) CY1118978T1 (da)
DK (1) DK1648507T3 (da)
ES (1) ES2619171T3 (da)
HR (1) HRP20170342T1 (da)
HU (1) HUE033129T2 (da)
IL (1) IL172679A (da)
LT (1) LT1648507T (da)
NO (2) NO337619B1 (da)
PL (1) PL1648507T3 (da)
PT (1) PT1648507T (da)
RU (1) RU2396981C2 (da)
SI (1) SI1648507T1 (da)
WO (1) WO2005009465A1 (da)
ZA (1) ZA200601584B (da)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US20090191213A9 (en) * 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
DE602004030464D1 (de) * 2003-07-02 2011-01-20 Innate Pharma Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
JP2006528627A (ja) * 2003-07-24 2006-12-21 ウニヴェルシタ・デッリ・ストゥーディ・ディ・ペルージャ アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物
KR101299599B1 (ko) 2003-07-24 2013-08-23 위니베르시따 데글리 스뚜디 디 뻬루지아 Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을 높이는 방법 및 조성물
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
WO2005092925A2 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2006003179A2 (en) * 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
WO2006016276A2 (en) 2004-08-03 2006-02-16 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2325207B1 (en) 2004-11-12 2017-03-15 Xencor, Inc. FC variants with altered binding to FCRN
EP3026063A1 (en) 2004-12-28 2016-06-01 Innate Pharma S.A. Monoclonal antibodies against nkg2a
DK1835937T3 (da) * 2005-01-06 2012-07-23 Novo Nordisk As Sammensætninger og fremgangsmåder til behandling af virusinfektion
ATE531733T1 (de) 2005-01-06 2011-11-15 Novo Nordisk As Kir-bindende wirkstoffe und verfahren zu ihrer verwendung
EP2446897A1 (en) 2005-01-06 2012-05-02 Novo Nordisk A/S Anti-KIR combination treatments and methods
US20060275282A1 (en) * 2005-01-12 2006-12-07 Xencor, Inc. Antibodies and Fc fusion proteins with altered immunogenicity
JP2008540569A (ja) * 2005-05-12 2008-11-20 ザイモジェネティクス， インコーポレイテッド 免疫系を調整するためにＢ７ファミリーメンバーであるｐＮＫｐ３０を使用する方法
DK1931709T3 (da) * 2005-10-03 2017-03-13 Xencor Inc Fc-varianter med optimerede fc-receptorbindingsegenskaber
US7973136B2 (en) * 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
CN101300272B (zh) * 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
JP5829004B2 (ja) * 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー／エス 抗ｎｋｇ２ａ抗体とその使用
ME01786B (me) 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
US8394374B2 (en) * 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
CA3102704A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc FC variants with modified binding to FCRN
EP2247619A1 (en) 2008-01-24 2010-11-10 Novo Nordisk A/S Humanized anti-human nkg2a monoclonal antibody
WO2010065939A1 (en) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Combination therapy to enhace nk cell mediated cytotoxicty
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
KR101497196B1 (ko) 2010-02-11 2015-02-27 에프. 호프만-라 로슈 아게 3차원 ａｄｃｃ 자연 살해 형광 활성화된 세포 분류 분석
WO2011133819A2 (en) * 2010-04-21 2011-10-27 Ventirx Pharmaceuticals, Inc. Methods of enhancing antibody-dependent cellular cytotoxicity
TWI664191B (zh) * 2010-11-22 2019-07-01 天賜製藥公司 Ｎｋ細胞調節治療及治療血液惡性疾病之方法
MX347514B (es) * 2011-05-25 2017-04-28 Innate Pharma Sa Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios.
BR112013032217B1 (pt) 2011-06-17 2021-01-19 Novo Nordisk A/S uso de um anticorpo anti-nkg2a
US20140234342A1 (en) 2011-06-21 2014-08-21 Innate Pharma Nkp46-mediated nk cell tuning
LT2904011T (lt) 2012-10-02 2017-11-10 Bristol-Myers Squibb Company Anti-kir antikūnų ir anti-pd-1 antikūnų derinys, akirtas vėžio gydymui
JP6553515B2 (ja) * 2012-12-20 2019-07-31 メディミューン，エルエルシー 免疫複合体の製造方法
CA2899241C (en) * 2013-02-20 2023-03-28 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
EP3066128B1 (en) 2013-11-06 2018-10-31 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
SG11201606789SA (en) * 2014-03-14 2016-09-29 Innate Pharma Humanized antibodies with increased stability
TWI717319B (zh) * 2014-05-27 2021-02-01 中央研究院 得自類桿菌屬之岩藻糖苷酶及其用途
WO2015197593A1 (en) * 2014-06-27 2015-12-30 Innate Pharma MULTISPECIFIC NKp46 BINDING PROTEINS
SG11201701340RA (en) * 2014-09-16 2017-03-30 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
CA2959821A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
LT3283107T (lt) 2015-04-17 2020-09-10 Bristol-Myers Squibb Company Kompozicija apimanti ipilimumabo ir nivolumabo kombinaciją
SG11201708706YA (en) 2015-05-06 2017-11-29 Snipr Tech Ltd Altering microbial populations & modifying microbiota
BR112018000252A2 (pt) * 2015-07-07 2019-02-12 INSERM (Institut National de la Santé et de la Recherche Médicale) métodos e composições farmacêuticas para intensificar atividades de eliminação de célula nk
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
JP6944925B2 (ja) * 2015-07-24 2021-10-06 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 組織浸潤ｎｋ細胞を検出する方法
SG10201913748QA (en) * 2015-08-11 2020-03-30 Univ Osaka Antibody
EP3359168A4 (en) 2015-10-06 2019-08-07 Regents of the University of Minnesota THERAPEUTIC COMPOUNDS AND METHODS
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017201502A1 (en) 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN109414490A (zh) * 2016-07-01 2019-03-01 小利兰·斯坦福大学理事会 抑制性免疫受体抑制方法和组合物
CN106635998B (zh) * 2016-09-14 2018-01-09 深圳市默赛尔生物医学科技发展有限公司 抗体调控的双抗原特异性t细胞及其制备方法和应用
AU2017335732A1 (en) 2016-09-27 2019-04-04 Board Of Regents, The University Of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
RU2755903C2 (ru) 2016-10-12 2021-09-22 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Способы и композиции для tusc2-иммунотерапии
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
KR20240023449A (ko) 2017-02-08 2024-02-21 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
SG10202110594UA (en) 2017-03-31 2021-11-29 Bristol Myers Squibb Co Methods of treating tumor
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
JP6647240B2 (ja) * 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3444276A1 (en) 2017-08-17 2019-02-20 Onkocellular Limited Improved cancer treatment using nk cells
US20200239577A1 (en) 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
JP2021512630A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ受容体を標的とする抗体可変ドメイン
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
CA3094458A1 (en) 2018-03-25 2019-10-31 Snipr Biome Aps. Treating & preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP3774911A1 (en) 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
TW202033555A (zh) 2018-11-16 2020-09-16 美商必治妥美雅史谷比公司 抗nkg2a抗體及其用途
KR20210109564A (ko) 2018-12-21 2021-09-06 옹쎄오 신규의 컨쥬게이티드 핵산 분자 및 이의 용도
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
JP2023532768A (ja) 2020-07-07 2023-07-31 バイオエヌテック エスエー Ｈｐｖ陽性癌の治療用ｒｎａ
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023240182A1 (en) 2022-06-08 2023-12-14 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR401702A (fr) 1908-08-04 1909-09-13 Charles Marenghi Et Cie Soc Dispositif permettant d'imiter mécaniquement la mandoline
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
CH686365A5 (de) 1992-10-06 1996-03-15 Werner Hofliger Mobilkran.
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
AU732306B2 (en) 1997-10-14 2001-04-12 Chugai Seiyaku Kabushiki Kaisha Potentiator for antibody against lymphoid tumor
US5843597A (en) 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
JPH11279009A (ja) 1998-03-26 1999-10-12 Sumitomo Chem Co Ltd 除草剤組成物
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
BR9913645A (pt) 1998-08-11 2001-09-25 Idec Pharma Corp Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
AU783899B2 (en) 1999-11-15 2005-12-22 Innate Pharma S.A.S. Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
PE20010833A1 (es) 1999-12-20 2001-09-08 Siemens Energy And Automation Inc Sistema, procedimiento y aparato para conectar fuentes electricas en serie bajo plena carga
FR2804027B1 (fr) 2000-01-20 2002-08-30 Monoclonal Antibodies Therapeu Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
PL358215A1 (en) 2000-03-24 2004-08-09 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
WO2002034290A2 (en) * 2000-10-23 2002-05-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
WO2002050122A2 (en) 2000-12-18 2002-06-27 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Means for the diagnosis and therapy of ctcl
US20030095965A1 (en) * 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
DK1436427T3 (da) * 2001-10-19 2008-12-08 Chru Tours Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
AU2003294930B2 (en) * 2002-12-23 2008-12-04 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same
DE602004030464D1 (de) 2003-07-02 2011-01-20 Innate Pharma Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
KR101299599B1 (ko) 2003-07-24 2013-08-23 위니베르시따 데글리 스뚜디 디 뻬루지아 Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을 높이는 방법 및 조성물
US8210374B2 (en) 2003-12-02 2012-07-03 Alfred Knox Harpole Rackable collapsible stackable unit

Also Published As

Publication number Publication date
KR20060038461A (ko) 2006-05-03
JP2014240426A (ja) 2014-12-25
NO20150493L (no) 2006-01-24
BRPI0412890B1 (pt) 2019-05-14
SI1648507T1 (sl) 2017-07-31
WO2005009465A1 (en) 2005-02-03
US20110008335A1 (en) 2011-01-13
RU2396981C2 (ru) 2010-08-20
CY1118978T1 (el) 2018-01-10
PL1648507T3 (pl) 2017-07-31
JP2012051889A (ja) 2012-03-15
US7803376B2 (en) 2010-09-28
CN102772798A (zh) 2012-11-14
US20050037002A1 (en) 2005-02-17
IL172679A (en) 2011-04-28
EP1648507B1 (en) 2017-01-25
EP2292264A2 (en) 2011-03-09
LT1648507T (lt) 2017-04-25
BRPI0412890A (pt) 2006-10-03
AU2004258747A1 (en) 2005-02-03
CN104645327A (zh) 2015-05-27
CN1829530A (zh) 2006-09-06
KR101299599B1 (ko) 2013-08-23
ZA200601584B (en) 2007-05-30
KR20120063562A (ko) 2012-06-15
NO337619B1 (no) 2016-05-09
PT1648507T (pt) 2017-03-20
CA2532547A1 (en) 2005-02-03
RU2006105642A (ru) 2006-06-27
BRPI0412890B8 (pt) 2021-05-25
NO20056049L (no) 2006-04-24
JP5642328B2 (ja) 2014-12-17
AU2004258747B2 (en) 2009-11-19
US9090876B2 (en) 2015-07-28
EP2292264A3 (en) 2012-12-19
ES2619171T3 (es) 2017-06-23
JP6290751B2 (ja) 2018-03-07
US10059765B2 (en) 2018-08-28
HUE033129T2 (en) 2017-11-28
JP5665702B2 (ja) 2015-02-04
EP1648507A1 (en) 2006-04-26
HRP20170342T1 (hr) 2017-05-19
IL172679A0 (en) 2006-04-10
CA2532547C (en) 2020-02-25
NO341586B1 (no) 2017-12-11
JP2006528626A (ja) 2006-12-21
CN102772798B (zh) 2016-01-13
US20150299319A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
DK1648507T3 (da) Fremgangsmåder og sammensætninger til øgning af effektiviteten af terapeutiske antistoffer ved anvendelse af forbindelser, der potenserer nk-celler
RU2376315C2 (ru) Композиция и способ регулирования активности естественных клеток-киллеров
CN110494451A (zh) 靶向tim-1的嵌合抗原受体
CN115052902B (zh) 淋巴细胞-抗原提呈细胞共刺激因子及其应用
TW202011999A (zh) Dll3 的嵌合受體及其使用方法
CN117285642A (zh) 制导和导航控制蛋白及其制备和使用方法
US20240109974A1 (en) Humanized antibody against tnfr2 and use thereof
CA2542840A1 (en) Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
KR20230166096A (ko) Cldn18.2 항원 결합 단백질 및 이의 적용
JP2006528627A (ja) アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物
WO2024090458A1 (ja) 抑制型ｋｉｒに対するアゴニストを用いた免疫拒絶の回避方法
CN112638949B (zh) 抗b7s1多肽及其用途
MXPA06000841A (es) Metodos y composiciones para aumentar la eficiencia de anticuerpos terapeuticos que utilizan compuestos para potenciar celulas nk